Aristides Capital LLC Grows Stock Holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Aristides Capital LLC raised its stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 20.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 241,587 shares of the company’s stock after buying an additional 41,587 shares during the period. Eton Pharmaceuticals makes up approximately 0.7% of Aristides Capital LLC’s holdings, making the stock its 23rd largest holding. Aristides Capital LLC owned about 0.93% of Eton Pharmaceuticals worth $3,218,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of ETON. Envestnet Asset Management Inc. acquired a new position in Eton Pharmaceuticals during the fourth quarter worth $236,000. JPMorgan Chase & Co. boosted its position in shares of Eton Pharmaceuticals by 7,086.9% in the 4th quarter. JPMorgan Chase & Co. now owns 51,961 shares of the company’s stock worth $692,000 after buying an additional 51,238 shares in the last quarter. Hillsdale Investment Management Inc. acquired a new stake in Eton Pharmaceuticals in the 4th quarter valued at about $226,000. Thompson Siegel & Walmsley LLC grew its stake in Eton Pharmaceuticals by 11.3% in the 4th quarter. Thompson Siegel & Walmsley LLC now owns 128,039 shares of the company’s stock valued at $1,705,000 after acquiring an additional 13,009 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in Eton Pharmaceuticals by 230.5% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,878 shares of the company’s stock valued at $2,862,000 after acquiring an additional 149,864 shares in the last quarter. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Eton Pharmaceuticals Price Performance

NASDAQ:ETON opened at $11.83 on Friday. The firm has a market cap of $317.26 million, a PE ratio of -53.77 and a beta of 1.34. The firm has a 50 day simple moving average of $15.26 and a 200-day simple moving average of $12.16. Eton Pharmaceuticals, Inc. has a 1-year low of $3.03 and a 1-year high of $18.41.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02). Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. The company had revenue of $11.65 million during the quarter, compared to the consensus estimate of $10.53 million. As a group, sell-side analysts expect that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on ETON shares. Craig Hallum increased their price target on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, March 19th. B. Riley reiterated a “buy” rating and set a $24.00 target price (up previously from $21.00) on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th. Finally, HC Wainwright reissued a “buy” rating and issued a $33.00 price target on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.